Rachel Jorge Dino Cossetti
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Rachel Jorge Dino Cossetti has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Adriana Telles
Centro de Oncologia, Hospital Sírio Libanês, Rua Dona Adma Jafet 91, São Paulo, 01308-050, Brazil
1 shared publication - Ana Paula Silva de Azevedo dos Santos
Center of Biological and Health Sciences, Federal University of Maranhão, Bacanga Campus, São Luís 65080-805, MA, Brazil
1 shared publication - André Alvares Marques Vale
Center of Biological and Health Sciences, Federal University of Maranhão, Bacanga Campus, São Luís 65080-805, MA, Brazil
1 shared publication - Brenda Gumz
Hospital Sirio-Libanes, Brasilia, DF, Brazil
1 shared publication - Bruno de Paulo Ribeiro
Federal University of Maranhão, São Luís, MA, Brazil
1 shared publication - Ed Carlos Rey Moura
Federal University of Maranhão, Brazil
1 shared publication
Latest Publications
- Open Access
- 6 February 2025
- Published by Brazilian Journals in REVISTA DELOS
- Vol. 18 (64)
Papiloma nasal invertido: revisão sistemática sobre potencial de malignização e manejo clínico
O presente estudo caracteriza-se como uma revisão sistemática da literatura, cujo objetivo é investigar a problemática da malignização do Papiloma Nasal Invertido, um tipo de tumor que, inicialmente benigno, pode evoluir para maligno devido a tratamentos inadequados e cuidados insuficientes. Essa transformação pode resultar em diversos tipos de carcinoma, o que reforça a relevância de estudos mais aprofundados sobre o tema. Dada a escassez de pesquisas específicas nessa área, o presente estudo selecionou 19 artigos relevantes, dos quais 6 foram utilizados para a composição dos resultados. Esses artigos foram obtidos em diferentes bases de dados, como PUBMED, SCIELO e BVS, com a restrição de publicação nos últimos cinco anos. Os resultados indicam que, além da eliminação de potenciais fatores de risco, a prevenção, o diagnóstico precoce e o acompanhamento em longo prazo são cruciais para o manejo do Papiloma Nasal Invertido. Destaca-se ainda a alta taxa de recorrência desse tipo de tumor, o que torna o acompanhamento contínuo essencial para minimizar complicações e reduzir a probabilidade de malignização.
- 6 February 2025
- Published by Brazilian Journals in REVISTA DELOS
- Vol. 18 (64)
Open AccessPapiloma nasal invertido: revisão sistemática sobre potencial de malignização e manejo clínico
O presente estudo caracteriza-se como uma revisão sistemática da literatura, cujo objetivo é investigar a problemática da malignização do Papiloma Nasal Invertido, um tipo de tumor que, inicialmente benigno, pode evoluir para maligno devido a tratamentos inadequados e cuidados insuficientes. Essa transformação pode resultar em diversos tipos de carcinoma, o que reforça a relevância de estudos mais aprofundados sobre o tema. Dada a escassez de pesquisas específicas nessa área, o presente estudo selecionou 19 artigos relevantes, dos quais 6 foram utilizados para a composição dos resultados. Esses artigos foram obtidos em diferentes bases de dados, como PUBMED, SCIELO e BVS, com a restrição de publicação nos últimos cinco anos. Os resultados indicam que, além da eliminação de potenciais fatores de risco, a prevenção, o diagnóstico precoce e o acompanhamento em longo prazo são cruciais para o manejo do Papiloma Nasal Invertido. Destaca-se ainda a alta taxa de recorrência desse tipo de tumor, o que torna o acompanhamento contínuo essencial para minimizar complicações e reduzir a probabilidade de malignização.
- Open Access
- 25 January 2019
- Published by Springer Nature in BMC Research Notes
- Vol. 12 (1) , 59
High dose gabapentin does not alter tumor growth in mice but reduces arginase activity and increases superoxide dismutase, IL-6 and MCP-1 levels in Ehrlich ascites
The purpose of this study was to evaluate the effect of gabapentin on Ehrlich tumor growth in Swiss mice, a highly aggressive and inflammatory tumor model. Mice were grouped into sets of 5 animals and treated from days 2 to 8 with gabapentin 30 mg/kg body weight (G30) or 100 mg/kg body weight (G100), or normal sterile saline (control). The mice were euthanized on day 10. Tumor growth, tumoricidal agents and inflammatory cytokines levels were assessed. At day 10, G30 and G100 mice gained weight, but there were no differences in tumor cell count or in ascites volume. In G100, there was a reduction in arginase and an increase in SOD activities. There was an increase in IL-6 and MCP-1 levels, especially in G100, but no alterations in TNF-α. There was no direct evidence of tumor induction by gabapentin. However, the findings suggest that its use modulates immune response to a more effector and less deleterious profile, with increase in activity of anti-oxidant enzymes and in cytokines that favor activation of macrophages, which could improve the general status of the tumor host.
- 25 January 2019
- Published by Springer Nature in BMC Research Notes
- Vol. 12 (1) , 59
Open AccessHigh dose gabapentin does not alter tumor growth in mice but reduces arginase activity and increases superoxide dismutase, IL-6 and MCP-1 levels in Ehrlich ascites
The purpose of this study was to evaluate the effect of gabapentin on Ehrlich tumor growth in Swiss mice, a highly aggressive and inflammatory tumor model. Mice were grouped into sets of 5 animals and treated from days 2 to 8 with gabapentin 30 mg/kg body weight (G30) or 100 mg/kg body weight (G100), or normal sterile saline (control). The mice were euthanized on day 10. Tumor growth, tumoricidal agents and inflammatory cytokines levels were assessed. At day 10, G30 and G100 mice gained weight, but there were no differences in tumor cell count or in ascites volume. In G100, there was a reduction in arginase and an increase in SOD activities. There was an increase in IL-6 and MCP-1 levels, especially in G100, but no alterations in TNF-α. There was no direct evidence of tumor induction by gabapentin. However, the findings suggest that its use modulates immune response to a more effector and less deleterious profile, with increase in activity of anti-oxidant enzymes and in cytokines that favor activation of macrophages, which could improve the general status of the tumor host.
- Open Access
- 16 May 2012
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 10 (1) , 82
Whole body diffusion for metastatic disease assessment in neuroendocrine carcinomas: comparison with OctreoScan® in two cases
Neuroendocrine tumor (NET) patients must be adequately staged in order to improve a multidisciplinary approach and optimal management for metastatic disease. Currently available imaging studies include somatostatin receptor scintigraphy, like OctreoScan®, computed tomography (CT), scans and magnetic resonance imaging (MRI), which analyze vascular concentration and intravenous contrast enhancement for anatomic tumor localization. However, these techniques require high degree of expertise for interpretation and are limited by their availability, cost, reproducibility, and follow-up imaging comparisons. NETs significantly reduce water diffusion as compared to normal tissue. Diffusion-weighted imaging (DWI) in MRI has an advantageous contrast difference: the tumor is represented with high signal over a black normal surrounding background. The whole-body diffusion (WBD) technique has been suggested to be a useful test for detecting metastasis from various anatomic sites. In this article we report the use of DWI in MRI and WBD in two cases of metastatic pulmonary NET staging in comparison with OctreoScan® in order to illustrate the potential advantage of DWI and WBD in staging NETs.
- 16 May 2012
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 10 (1) , 82
Open AccessWhole body diffusion for metastatic disease assessment in neuroendocrine carcinomas: comparison with OctreoScan® in two cases
Neuroendocrine tumor (NET) patients must be adequately staged in order to improve a multidisciplinary approach and optimal management for metastatic disease. Currently available imaging studies include somatostatin receptor scintigraphy, like OctreoScan®, computed tomography (CT), scans and magnetic resonance imaging (MRI), which analyze vascular concentration and intravenous contrast enhancement for anatomic tumor localization. However, these techniques require high degree of expertise for interpretation and are limited by their availability, cost, reproducibility, and follow-up imaging comparisons. NETs significantly reduce water diffusion as compared to normal tissue. Diffusion-weighted imaging (DWI) in MRI has an advantageous contrast difference: the tumor is represented with high signal over a black normal surrounding background. The whole-body diffusion (WBD) technique has been suggested to be a useful test for detecting metastasis from various anatomic sites. In this article we report the use of DWI in MRI and WBD in two cases of metastatic pulmonary NET staging in comparison with OctreoScan® in order to illustrate the potential advantage of DWI and WBD in staging NETs.